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Abstract IgG4-related disease (IgG4-RD) is relatively a
new growing entity of immune-mediated origin, charac-
terized by a mass-forming lesion, the infiltration of IgG4-
positive plasma cells and occasionally elevated serum
IgG4. It is considered to be both a systemic inflammation
and sclerosing disease. The most common manifestations
are parotid and lacrimal swelling, lymphadenopathy and
autoimmune pancreatitis. Sclerosing cholangitis and
retroperitoneal fibrosis are among the other mentioned
frequent manifestations. The diagnosis should be
approved histo-pathologically but other conditions such as
lymphoma should be carefully excluded. Patients with
IgG4-RD respond beneficially to glucocorticoid therapy
especially when given at early onset stages. In some
cases, the combination of immunosuppressive agents is
required.
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A 68-year-old female was hospitalized due to new onset of
abdominal pains, on and off high systemic fever, weight
loss and increased inflammation markers (i.e., increased
erythrocyte sedimentation rate and C-reactive protein). On
abdominal computed tomography (CT), a retroperitoneal
mass was noticed, following which a guided biopsy was
performed. Histopathology clearly defined the mass to be
IgG4-related fibrosis (Figs. 1, 2). The patient was started
on oral corticosteroids, which resulted in a slight clinical
improvement (i.e., weight gain and improved general sta-
tus). However, when the abdominal CT was repeated, no
improvement in the mass appeared and it was even slightly
enlarged. Methotrexate was then added, and after three
months when no improvement was seen, it was replaced
with rituximab. The addition of rituximab was not benefi-
cial and fever episodes persisted. The mass became bigger
and heterogeneous on repeated abdominal CT. In this case,
IgG4-related fibrosis was suggested to be a masking finding
of underlying malignancy, and abdominal surgery was
planned. The mass was surgically removed and the
histopathological diagnosis of liposarcoma was estab-
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Introduction
IgG4-related disease (IgG4-RD) is increasingly recog-
nized as a serious condition of unknown etiology. It is
characterized as having specific locations and a specific
histopathology [1]. Previously, this disorder was known
as IgG4 multi-organ lymphoproliferative syndrome
(IgG4 MOSLP), IgG4 sclerosing disease, or IgG4-related
systemic plasmocytic syndrome (SIPS). Recently, it is
simply recognized as IgG4-RD, the main features of
which are tumor-like swelling of involved organs
(mainly lacrimal glands, salivary glands and the pan-
creas), in association with lymphoplasmacytic infiltrate
enriched in IgG4-positive plasma cells and variable
degrees of fibrosis with a characteristic ‘‘storiform pat-
tern’’ [2].
Fig. 1 Immunostaining for
IgG and IgG4 is strongly
positive in plasma cells. Arrow





diluted for Ventana Roche
detection kits in automated slide
strainer Benchmark Ultra
Fig. 2 Core tissue showing
mononuclear inflammation and
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Elevated IgG4 serum concentrations are noticed in
60–70 % of patients and responsiveness to glucocorti-
coids is reported, particularly in early stages of the dis-
ease. It is poorly defined, and its incidence in the general
population or among different geographic or ethnic
groups is indefinite. The estimated incidence in Japan is
about 2.6–10.6 per 106. While IgG4-RD occurs mostly in
middle-aged persons, the gender distribution differs
according to the involved organs. In general, IgG4-RD
affects males more than females, yet the group present-
ing only head and neck symptoms demonstrated an equal
sex distribution [2, 3].
Pathogenesis
Normal sera contain nine immunoglobulin isotypes: IgG1,
IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD and IgE [4]. IgG4
has a special specificity: (1) The concentration of IgG4 in
the serum is very low (less than 5 % of total IgG); in
contrast to IgG1-3, however, the variability of IgG4 serum
concentrations among healthy people reaches a factor of
more than 100 (normal range, 0.01 to 0.4 mg per milliliter)
and is stable within individuals [5]. (2) Despite the 95 %
homology of the constant domains of IgG4 heavy chains
with the other subclasses, there is weak or negligible
binding of IgG4 to both C1q and Fcc receptors, which is
attributable to amino acid differences within the second
constant domain [6]. IgG4 can bind with a low affinity to
Fcc receptor I (CD64), but not to the other Fcc receptors
(Fcc-RII-CD32, Fcc-RIII-CD16) [7]. (3) IgG4 molecules
are unable to cross-link antigens due to Fab-arm exchange,
and therefore, are unable to form immune complexes [8].
Instead, as shown in vitro analysis, they form ineffective
immune complexes with other IgG4 antibodies (by Fc–Fc
interaction). Therefore, IgG4 is considered uninvolved in
activating classical complement pathways effectively and
has traditionally been believed to play only a limited role in
immune activation. 4) IgG4 production is controlled by T
helper 2 cells, by producing interleukin 4 and 13, leading to
the production of both IgG4 and IgE [5].
IgG4 has a unique feature of exchanging Fab arms
(‘‘flip-flop’’ exchange of heavy ? light chains), thereby
generating a new blocking bivalent IgG4 with a bi-specific
reactivity. This characteristic provides a protecting effect
[1, 4]. In this respect, the level of IgG4 serum antibodies is
increased one to 2 months following immunotherapy and
in correlation with the success of this treatment in
improving allergic rhinitis [9]. In addition, human anti-
acetyl choline receptor IgG4 monoclonal antibodies were
experimentally demonstrated to have a degrading effect on
AChR when assessed on rhabdomyosarcoma TE671 cells.
However, these antibodies failed to demonstrate such a
degrading effect following their administration to rhesus
monkeys due to Fab-arm exchange and generation of bi-
specific IgG4 antibodies in the monkeys’ sera. Bi-specific
IgG4 antibodies were capable of blocking the AChR
degradation by IgG1 anti-AChR-specific monoclonal anti-
bodies [8].
In contrast to the hypothesis of being protective rather
than inflammatory, we know that IgG4 plays a central role
in the pathogenesis of some autoimmune diseases. For
example, anti-desmoglein-1 IgG4 antibodies are important
for the generation of cutaneous blisters in patients with
pemphigus vulgaris. Additionally, IgG4 antibodies are
probably involved in the pathogenesis of membranous
glomerulonephritis and thrombotic thrombocytopenic pur-
pura [1].
The pathogenesis of IgG4-RD is poorly understood,
raising the possibility of it being autoimmune or allergic in
origin [10]. As in all autoimmune diseases, finding a
specific autoantigen or autoantibody in IgG4-RD is nec-
essary to underscore a definitive role in autoimmunity.
Aiming to achieve this goal, many researchers have tried to
detect autoantigens or pathogens with molecular mimicry.
Among the many known autoantibodies identified so far,
non-specific antinuclear antibodies are detected in more
than half of patients with IgG4-RD. Antibodies against
carbonic anhydrase II and lactoferrin are the most fre-
quently detected in autoimmune pancreatitis (AIP) (54 and
73 %, respectively). Immune complex deposition was also
reported in the pancreas, kidneys, and other affected organs
[11]. Two studies have demonstrated molecular mimicry
between Helicobacter pylori (H. pylori) and constituents of
pancreatic cells, suggesting that gastric H. pylori infection
triggers AIP in genetically predisposed individuals through
antibody cross-reactivity. In the first study, significant
homology between human CA-II and a-carbonic anhydrase
of H. pylori was demonstrated [12]. In the second one,
94 % of patients with AIP had antibodies plasminogen-
binding protein of H. pylori, which displays homology with
that of ubiquitin-protein ligase E3 component n-recognin 2,
an enzyme expressed in pancreatic acinar cells [13]. As yet
autoimmunity has not been completely proved. Antibodies
directed against potential autoantigens as carbonic anhy-
drases, lactoferrin, pancreatic secretory trypsin inhibitor,
and trypsinogens, some of which are expressed in exocrine
glands, may come in association with systemic manifes-
tations of IgG4-RD. However, these autoantibodies are
lacking specificity for IgG4-RD and are not known to be of
the IgG4 subclass [13].
It also remains unclear whether IgG4 is an autoantibody
primarily expressed in IgG4-RD or is overexpressed sec-
ondarily in response to an unknown primary inflammatory
stimulus. The putative tendency of IgG4 antibodies to
fulfill anti-inflammatory functions and the fact that disease-
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specific IgG4 autoantibodies have not been detected in
IgG4-RD support the hypothesis that they are a secondary
response to inflammation [13].
IgG4-RD is also characterized by a dominance of Th2
immune response, where IL-4 and IL-13 cytokines were
proven to increase the production of IgG4 and IgE [14]. In
parallel with this, IgG4-RD is characterized by increased
numbers of T regulatory (Treg) cells and levels of
cytokines produced by them such as IL-10 and TGF-b in
both peripheral blood and affected tissues. In this respect,
IL-10 interferes with the Ig class switch contributing to
increase both IgE and IgG4 production. These findings are
consistent with the theory that the production of IgG4
in vivo is induced mainly by a Th2-cell-dominant immune
reaction, in the presence of increased IL-10 producing Treg
cells [4, 5, 14, 15].
Clinical manifestation
Many studies have reported that 60–90 % of patients with
IgG4-RD have multiple organ involvements [16]. IgG4-RD
is usually found incidentally when imaging or
histopathology procedures are performed. Asymptomatic
lymphadenopathy is common, and is present in 80 % of
patients with AIP; however, constitutional symptoms such
as fever and fatigue—though reported—are generally
absent at diagnosis [17]. In a cross-sectional study
involving 114 cases with multiple organ involvement,
lymphadenopathy was found in 41 % of patients [2].
Symptomatic lymphadenopathy, when present, was due to
mass effect, which may range up to 5 cms [18]. About
40 % of patients suffer usually from allergic diseases,
mainly allergic rhinitis or asthma (consistent with the
above-mentioned dominance of Th2 immune responses)
[14]. Yet, IgG4 Mikulicz disease and type 1 AIP are con-
sidered the two most common IgG4-related diseases. Initial
observations were made in patients with type 1 AIP, also
called lymphocytic sclerosing pancreatitis, which normally
affects elderly males. This condition often presents as
pancreatic mass or as painless obstructive jaundice, and can
be misdiagnosed as pancreatic cancer [19]. IgG4-related
cholangitis is the most common extra pancreatic manifes-
tation of type 1 AIP and may affect over 70 % of such
patients [17]. Normally, IgG4 Mikulicz disease presents as
a bilateral swelling of lacrimal and salivary glands but
without signs of dryness; unilateral involvement has also
been reported [19]. About 40 % of patients with IgG4-
related pancreatitis have, in addition, salivary or lacrimal
gland involvement, while AIP may be detected in only
17 % of patients presenting with sialadenitis (inflammation
of salivary glands) [20]. Sclerosing sialadenitis (Kuttner’s
tumor) often precedes AIP in patients who develop both
conditions. IgGRD is likely to be responsible for 25–50 %
of orbital pseudotumors and can cause orbital myositis
(IgG4-related orbital myositis) [21]. In some cases, patients
with idiopathic retroperitoneal fibrosis have histologic and
serologic changes consistent with IgG4-RD [22].
In a review in which 14 published cases of IgG4-related
retroperitoneal fibrosis were summarized, the involvement
of other organs included the pancreas (11 patients), sali-
vary glands (3 patients), lymph nodes (2 patients), one
affected the pituitary gland, and one the mediastinal
periaortitis. On the other hand, isolated IgG4-related
retroperitoneal fibrosis was also reported. IgG4-RD is
considered to be a cause of noninfectious aortitis. Data
have been derived from retrospective pathologic studies of
patients who had undergone aortic resections [23, 24]. In a
study of 638 patients, who underwent thoracic aortic
resections, three patients exhibited histology characteristics
of IgG4-RD, representing 9 % of the 33 cases with non-
infectious aortitis or 0.5 percent of the entire series of
thoracic resections [25]. Thyroid involvement in IgG4-RD
takes two forms: Riedel’s thyroiditis and the fibrous variant
of Hashimoto’s thyroiditis [26]. IgG4-related pulmonary
disease is mostly asymptomatic but may present with
cough, hemoptysis, and dyspnea or chest pain. Manifesta-
tions as pseudotumors and interstitial pneumonia have been
associated with AIP [27]. Visceral or parietal pleural
thickening may occur. The most common finding of renal
involvement in patients with IgG4-RD is tubulointerstitial
nephritis [28]. In a Japanese retrospective study of 153
patients with suspected IgG4-RD, 23 patients (15 %) were
identified with tubulointerstitial nephritis (TIN) secondary
to IgG4-RD, and 96 % of TIN patients exhibited extrarenal
manifestations, which included sialadenitis (83 %), lym-
phadenopathy (44 %), AIP (39 %), dacryoadenitis (30 %),
and lung lesions (26 %). Symptoms—when present—were
usually secondary to extrarenal manifestations. The
involvement of other organs or tissues in IgG4-RD
includes skin, liver (resembling autoimmune hepatitis),
stomach (lymphoplasmacytic associated with AIP), breast
(sclerosing mastitis and inflammatory pseudotumors of the
breast), hypopituitarism with IgG4-related hypophysitis,
pachymeningitis, prostatitis and constrictive pericarditis
[29–33].
Association with malignancy
Pancreato-biliary cancers and other malignancies were
reported to have increased IgG4 infiltration. The finding of
elevated numbers of IgG4 ? plasma cells within a tumor is
misleading and may mistakenly be considered as IgG4-RD.
In such cases, a needle biopsy sampling from the periphery
of a malignant neoplasm may lead to misdiagnoses of
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IgG4-RD. Some types of lymphoma have been reported in
patients with IgG4-RD. In one study involving 111 patients
with IgG4-RD (91 % with AIP), three cases of non-
Hodgkin lymphoma were found within three to five years
after diagnosing IgG4-RD. The standardized incidence
ratio was 16.0 (95 % CI 3.3–45.5), indicating an increased
risk of non-Hodgkin lymphoma [34]. In another series of
108 patients with IgG4-related pancreatitis, 18 cancers
were diagnosed in 15 patients within a median follow-up of
3.3 years. The highest risk was in the first year following
the diagnosis, and gastric cancer was the most common
involved, with the other organs being lung, prostate, colon,
non-Hodgkin lymphoma, bile duct, and thyroid [35]. In six
patients suffering from IgG4-related pancreatitis and can-
cer, the diagnosis of cancer was histologically approved
before being treated with corticosteroids. Interestingly,
IgG4-related pancreatitis remained in full remission after
successful treatment of the cancer. According to this
observation, the finding of IgG4-RD is considered a para-
neoplastic syndrome in some cases. The possibility that
patients with IgG4-RD have increased prevalence of
malignancy requires further study.
Diagnosis
IgG4RD should be suspected if any of the following is
present: Pancreatitis of unknown origin, sclerosing
cholangitis or bilateral salivary and/or lacrimal gland
enlargement. Sah et al. reported that normal IgG4 serum
levels are present in 20–30 % of patients with typical IgG4
histopathological infiltrates [36]. Thus, elevated serum
levels of IgG4 are considered characteristic of, but not
specific to, IgG4-RD. A multinational, multidisciplinary
group of experts defined criteria for the diagnosis of IgG4-
RD [37]. The three major histopathological features asso-
ciated with IgG4-related disease are as follows:
1. Dense lymphoplasmacytic infiltrate
2. Focally arranged fibrosis in a storiform pattern
3. Obliterative phlebitis.
The other histopathological features associated with
IgG4-RD are as follows: 1. Phlebitis without obliteration of
the lumen; and 2. Increased numbers of eosinophils. These
two features alone are neither sensitive nor specific for the
diagnosis of IgG4-RD. A confident pathological diagnosis
of IgG4-RD necessitates the presence of two of the three
major histological features. The usually detected features
are a dense lymphoplasmacytic infiltrate and storiform-
type fibrosis. The group of experts mentioned above pro-
posed a scheme and three options for the diagnosis of
IgG4-related disease that is based primarily on the mor-
phological appearance on biopsy (Table 1). Three clinical
options were suggested:
1. Histology highly suggestive of IgG4-RD: This cate-
gory requires at least two of the major histological
features (a dense lymphoplasmacytic infiltrate,
Table 1 Diagnostic algorithm of IgG4-related disease



















Lacrimal gland [100 x [100 x
Salivary gland [100 x [100 x
Lung (surgical
specimen)
[50 x [50 x
Lung (biopsy) [20 x [20 x
Pancreas (surgical
specimen)
[50 x [50 x
Pancreas (biopsy) [10 x [10 x
Bile duct (surgical
specimen)
[50 x [50 x
Bile duct (biopsy) [10 x [10 x
Liver (surgical
specimen)
[50 x [50 x
Liver (biopsy) [10 x [10 x
Aorta [50 x [50 x
Retroperitoneum [30 x [30 x
IgG4 ?/IgG ? plasma cell ration[40 % is a mandatory for histological diagnosis of IgG4-RD
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storiform-type fibrosis and obliterative phlebitis).
Exceptions are the lymph nodes, lung, minor salivary
glands and the lacrimal gland, where both storiform
fibrosis and obliterative phlebitis may be absent
(Table 2). In this case, one major histological feature
compatible with IgG4-RD might suffice for dacryoad-
enitis (37). The required number of IgG4 ? plasma
cells (cell/hpf) for establishing the diagnosis of IgG4-
RD is broad and in accordance with the affected
organs, ranging from 10 to 200 cells/hpf. The IgG4 ?/
IgG ? cell ratio of[ 40 % was also suggested as a
requirement for a full diagnosis. In the case of aortic
specimens, a cell ratio of [50 % is considered a
minimal requirement for diagnosis due to the fact that
atherosclerosis giant cell arteritis and infectious aortitis
may have a IgG4 ?/IgG ? ratio close to 40 % [23].
2. Probable histological features of IgG4-RD: These
cases lack the full histopathological features associated
with IgG4-RD, and therefore, require additional clin-
ical, serological, or radiological findings to confirm a
full diagnosis. Of these, IgG4 serum[135 mg/dl and
another organ involvement based on radiological or
pathological examination are the most common.
3. Insufficient histopathological evidence of IgG4-RD:
Patients in this category are not entirely excluded from
a diagnosis of IgG4-RD. Sampling artifact, the effects
of previous therapy, and progression to a fibrotic stage
may constitute potential reasons for making the
diagnosis.
To establish the extent of disease, because of the fre-
quency of subclinical features and the involvement of two
organs, a CT scan of chest, abdomen, and pelvis should be
performed. Organ infiltration in IgG4RD demonstrates
high uptake on gallium scan and positron emission
tomography-computed tomography (PET-CT) [38]. When
available, PET-CT is considered at baseline.
Several diseases, being outside the range of IgG4-RD, are
associated with increased numbers of IgG4 ? plasma cells
in tissue. These include: (1) Inflammatory diseases: primary
sclerosing cholangitis, ANCA-associated vasculitis,
rheumatoid arthritis, inflammatory bowel disease, cutaneous
plasmocytosis, and autoimmune atrophic gastritis (perni-
cious anemia) [39, 40]. None of these conditions, however,
consistently show IgG4-rich inflammation and all lack the
characteristic histopathological features of IgG4-RD. (2)
Lymphoma: both extranodal marginal zone lymphomas and
sometimes follicular lymphomas and angioimmunoblastic
lymphomas can mimic IgG4-RD. In cases of possible IgG4-
RD with plasma cells exhibiting atypical features, low-grade
B-cell lymphomas must be excluded. The majority of infil-
trating lymphocytes in IgG4RD are T-and B lymphocytes,
and are mostly found in nodular aggregates, often within
reactive germinal centers [37].
Differential diagnosis
The differential diagnosis of IgG4-RD depends upon the
involved organ and clinical presentation. Differential
diagnosis of AIP type 1 includes other types of pancreatitis
(e.g., biliary, alcoholic, drug induced), type 2 AIP (young
adults with inflammatory bowel disease) and adenocarci-
noma of pancreas [38]. Differentiation is usually difficult
when based on clinical and radiological findings. For
example, painless jaundice is common to both AIP type 1
and pancreatic adenocarcinoma. In some cases, patients
have mistakenly undergone Whipple procedures with the
intention of treating pancreatic cancer. IgG4-RD of sali-
vary glands has many common features with Sjo¨gren’s
syndrome (SS). Clinical features that are helpful in dis-
tinguishing between SS and IgG4-RD include relatively
mild dryness of the eyes and of the mouth, a higher fre-
quency of allergic rhinitis and bronchial asthma, a higher
frequency of AIP and interstitial nephritis and low fre-
quencies of autoantibodies (including RF, ANA, anti-SSA,
and anti-SSB) [41, 42].
The clinical differentiation between primary sclerosing
cholangitis, cholangiocarcinoma and IgG4-related scleros-
ing cholangitis is difficult, but distinguishing between the
Table 2 Variability of histopathological findings in certain organs
Inflammation Storiform fibrosis Obliterative phlebitis
Lacrimal gland No special features Usually collagenous
Fibrosis
Sometimes lacks
Salivary gland Associated with lymphoid follicle formation Rare in parotid and minor salivary glands Sometimes lacks
Lymph node No special features Seen in inflammatory pseudotumor like lesion Usually lacks
Lung Aggregates of neutrophils Sometimes lacks No special features
Kidney No special features No special features Less common, especially in
needle biopsy
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diseases is critical because of the drastically different
therapies and prognoses. Differentiation could be done
using the classification of Nakazawa et al., where IgG4-
related sclerosing cholangitis is classified into four types
according to findings in the cholangiograms [43, 44]. IgG4-
RD can also mimic sarcoidosis. In one study observing
patients with sarcoidosis due to bilateral hilar adenopathy
and/or lung nodules on a chest CT, patients with IgG4-RD
were found among a subset with elevated IgG4 serum,
which also displays significantly higher levels of IgG4,
IgG4/IgG and IgG4/IgG3 in bronchoalveolar lavage com-
pared with those with normal IgG4 serum levels [45].
Treatment
The issue of how to treat IgG4-RD is based on the expe-
rience from observational data, case reports and small
series, most of which came from patients with AIP [17].
There are no randomized trials that have compared and
evaluated different approaches to the treatment of IgG4-
RD. IgG4-RD is responsive to steroids, which remain the
first line of therapy. Responsiveness is expected to be
within weeks, including symptomatic improvement,
reductions in the size of masses or organ enlargement,
improvement in organ function, and usually a decrease in
IgG4 serum levels. However, some patients respond only
within a few months, some relapse, and others respond
partially or not at all. Less responsive patients are those
with more advanced fibrotic changes, but such cases have
not been well defined. In a few case reports, spontaneous
remission with regression of organ infiltrates was reported.
The measurement of IgG4 serum concentration as an
indicator of disease activity remains controversial [30]. In
patients with elevated IgG4 serum concentrations at baseline,
such concentrations may decrease with glucocorticoid treat-
ment, but they remain above the normal values in most cases
[36]. The value of IgG4 serum concentrations in predicting
disease relapse is highly questionable, mostly due to limited
follow-up periods. In some patients, the monitoring of IgG4
concentrations may indicate early relapse; however, disease
relapses were recorded in 10 % of patients having normal
IgG4 serum concentrations [46]. Spontaneous remission with
regression of organ infiltrates is very rare.
The involvement of vital organs in IgG4-RD should be
treated aggressively to avoid serious organ dysfunction and
failure. Untreated IgG4-RD often progresses to extensive
fibrosis, but some manifestations of the disease remain
stable over time and do not require immediate treatment.
For example, for IgG4-related lymphadenopathy or inci-
dentally-detected lung nodules, watchful waiting is con-
sidered to be appropriate. Reports of indolent cases of
lymphadenopathy persisting for decades have been
described [18]. Prednisolone at a dose of 0.6 mg per kilo of
body weight per day for 2–4 weeks is recommended by a
consensus statement from 17 referral centers in Japan.
They also recommended tapering down the level of pred-
nisolone over a period of 3–6 months to 5 mg per day, and
continuing at a maintenance dose between 2.5 and 5.0 mg
per day for up to 3 years. Discontinuing glucocorticoids
entirely within 3 months is considered another approach
[46, 47]. Azathioprine, mycophenolate mofetil, and
methotrexate are offered as glucocorticoid-sparing agents
or remission-maintenance drugs, although their efficacy
has never been tested in clinical trials. A disease responder
index is a tool suggested by the Organizing Committee of
the International IgG4-related Disease Symposium to
detect changes in disease activity and to quantify objec-
tively the treatment response by providing standardized
outcome measures [48].
By recurrence or refractoriness, B-cell depletion with
rituximab can be attempted and is considered a useful
approach. In two studies (consisting altogether of 14
patients), the clinical and serologic responses to B lym-
phocyte depletion therapy in IgG4-RD patients who
remained refractory to steroids and DMARDs were asses-
sed. Treatment with rituximab (2 infusions of 1000 mg,
15 days apart) led to prompt clinical and serologic
improvement in these patients with refractory IgG4-RD
within one month of starting rituximab. One patient with
advanced thyroid fibrosis did not show improvement in the
thyroid gland, but disease did not progress to involve new
organs. Four patients were re-treated with RTX after
6 months, two patients because of symptom recurrence and
increasing IgG4 concentration, and the other two because
of physician discretion. Repeated courses of RTX main-
tained their effectiveness and further decreased IgG4 con-
centrations. The reduction in IgG-subclass levels appeared
to be specific for IgG4. Rituximab achieves its effects in
IgG4-RD by depleting B lymphocytes that replenish short-
lived IgG4-secreting plasma cells [49, 50]. Patients with
significant fibrosis in biopsy are less likely to have a
response to glucocorticoids and rituximab and have a poor
prognosis.
The natural history of IgG4-RD is not well defined.
Various complications influencing morbidity and mortality
in untreated patients were observed. These complications
include cirrhosis and portal hypertension; retroperitoneal
fibrosis; complications from aortic aneurysms, including
dissection; biliary obstruction; diabetes mellitus; and others
[17, 22]. Sustained benefit may be observed during therapy,
but relapses are common after discontinuation of therapy.
In conclusion, IgG4-RD remains a field not yet fully
explored or understood. Early and efficient therapies aim-
ing to achieve a beneficial outcome, and to improve
prognosis are still required. Malignancy should be
Autoimmun Highlights (2015) 6:7–15 13
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considered in each case of IgG4-RD to remove as early as
possible.
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